retatrutide parkinson's clinical trial New Weight Loss Drug Retatrutide: My Patient's 85-Pound Journey (And What The Emerging Role of GLP-1

JAMA Netw Open 3(10):e2020836 Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O et al (2021) Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: A phase 2 randomized clinical trial

Ozempic (semaglutide) has been extensively studied in clinical trials, demonstrating its effectiveness in supporting weight loss for individuals with obesity or overweight conditions

Mainstay treatments are renin-angiotensin-aldosterone system inhibitors, mineralocorticosteroid antagonists and -blockers, and, as mentioned earlier, SGLT-2 inhibitors, especially in people with comorbid diabetes

It is not a GLP-1, it doesnt affect insulin, and it doesnt slow gastric emptying

15,16 Jennings et al 15 demonstrated a significant decrease in weight (6.5 kg), HS Physicians Global Assessment (HS-PGA) (from 4 to 1), DLQI (from 24 to 14), and analgesic use (from daily to not daily) but no decrease in CRP (from 3 mg/dL) after eight weeks of treatment

The larger transformation was a sense of control